These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11140155)

  • 1. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies.
    Székely J; Esik O
    Strahlenther Onkol; 2000 Dec; 176(12):584-5. PubMed ID: 11140155
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of palifermin administered as the standard dose and as a collapsed dose in patients with hematologic malignancies.
    Zia-Amirhosseini P; Hurd DD; Salfi M; Cheah TC; Aycock J; Cesano A
    Pharmacotherapy; 2007 Oct; 27(10):1353-60. PubMed ID: 17896890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment.
    Miralbell R; Sancho G; Bieri S; Carrió I; Helg C; Brunet S; Martin PY; Sureda A; Gomez De Segura G; Chapuis B; Estorch M; Ozsahin M; Keller A
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):809-16. PubMed ID: 14967438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome after static intensity-modulated total body radiotherapy using compensators stratified by pediatric and adult cohorts.
    Schneider RA; Schultze J; Jensen JM; Hebbinghaus D; Galalae RM
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):194-202. PubMed ID: 17869024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials.
    Horan JT; Liesveld JL; Fernandez ID; Lyman GH; Phillips GL; Lerner NB; Fisher SG
    Bone Marrow Transplant; 2003 Aug; 32(3):293-8. PubMed ID: 12858201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
    van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
    Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized comparison of single-dose versus hyperfractionated total-body irradiation in patients with hematologic malignancies.
    Girinsky T; Benhamou E; Bourhis JH; Dhermain F; Guillot-Valls D; Ganansia V; Luboinski M; Perez A; Cosset JM; Socie G; Baume D; Bouaouina N; Briot E; Beaudre A; Bridier A; Pico JL
    J Clin Oncol; 2000 Mar; 18(5):981-6. PubMed ID: 10694547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Total body irradiation with or without lung shielding for allogeneic bone marrow transplantation.
    Labar B; Bogdanić V; Nemet D; Vrtar M; Mrsić M
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():108. PubMed ID: 2697391
    [No Abstract]   [Full Text] [Related]  

  • 9. Third biannual report of the Cochrane Haematological Malignancies Group.
    Kober T; Skoetz N; Trelle S; Bohlius J; Engert A;
    J Natl Cancer Inst; 2005 Aug; 97(16):E2. PubMed ID: 16106014
    [No Abstract]   [Full Text] [Related]  

  • 10. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
    Yamada MF; Miyamura K; Fujiwara T; Kohata K; Okitsu Y; Ohguchi H; Yamamoto J; Yokoyama H; Tomiya Y; Ishizawa K; Kameoka J; Harigae H
    Transplant Proc; 2008 Dec; 40(10):3637-42. PubMed ID: 19100456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
    Mattsson J; Uzunel M; Remberger M; Hassan M
    Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies.
    Okada M; Fujimori Y; Misawa M; Kai S; Nakajima T; Okikawa Y; Satake A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Tamaki H; Ikegame K; Hara H; Ogawa H
    Biol Blood Marrow Transplant; 2008 Aug; 14(8):896-903. PubMed ID: 18640573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing oral mucositis in patients with hematologic malignancies.
    J Support Oncol; 2006 Feb; 4(2):79. PubMed ID: 16499126
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduced-intensity conditioning regimen using low-dose total body irradiation before allogeneic transplant for hematologic malignancies: Experience from the European Group for Blood and Marrow Transplantation.
    Belkacémi Y; Labopin M; Hennequin C; Hoffstetter S; Mungai R; Wygoda M; Lundell M; Finke J; Aktinson C; Lorchel F; Durdux C; Basara N
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):544-51. PubMed ID: 17141976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
    Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
    Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-intensity conditioning regimens in malignant haematological diseases.
    Buffart TE; Janssen JJ; Huijgens PC
    Neth J Med; 2005 Feb; 63(2):43-51. PubMed ID: 15766008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of dose homogenization and radiation carcinogenesis risk in total body irradiation for bone marrow transplantation.
    Oysul K; Dirican B; Beyzadeoglu M; Sürenkok S; Arpaci F; Pak Y
    Neoplasma; 2003; 50(5):372-6. PubMed ID: 14628091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
    Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
    J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total body irradiation, fludarabine, melphalan, and allogeneic hematopoietic stem cell transplantation for advanced pediatric hematologic malignancies.
    Petropoulos D; Worth LL; Mullen CA; Madden R; Mahajan A; Choroszy M; Ha CS; Champlin RC; Chan KW
    Bone Marrow Transplant; 2006 Mar; 37(5):463-7. PubMed ID: 16435013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
    Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.